Institutional Stake: T. Rowe Price Owns 6.1% of ALKS

Rhea-AI Filing Summary

T. Rowe Price Associates, Inc. reported beneficial ownership of 10,041,900 shares of Alkermes plc common stock, representing 6.1% of the class as of June 30, 2025. The firm reports sole voting power for 9,983,207 shares and sole dispositive power for 10,041,900 shares on a Schedule 13G/A.

The filing identifies T. Rowe Price as an investment adviser filing under Rule 13d-1(b) and certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The Schedule is signed by Ellen York, Vice President, dated August 14, 2025.

Positive

• T. Rowe Price reports a significant institutional stake of 10,041,900 shares, or 6.1% of Alkermes common stock
• Filing states holdings are acquired and held in the ordinary course and not for the purpose of changing control

Negative

• None.

Insights

Financial Analyst

TL;DR: Institutional investor T. Rowe Price holds a material 6.1% stake in Alkermes; reported as held in the ordinary course.

The Schedule 13G/A documents a significant passive holding: 10,041,900 shares (6.1%) with sole voting power on 9,983,207 shares. As an investment adviser filing under Rule 13d-1(b), the reporting indicates passive ownership rather than an intent to seek control. For investors, the filing confirms concentration of institutional ownership but contains no operational or financial changes.

Corporate Governance Expert

TL;DR: Ownership disclosure is material for governance monitoring but the filing disclaims any control intent.

The filing explicitly states the position was acquired and is held in the ordinary course and not for influencing control. The reported sole voting power of 9,983,207 is relevant for proxy and engagement considerations. No group affiliations or coordinated action are indicated, and there is no request or assertion of board influence in this filing.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

ALKERMES PLC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

G01767105

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G01767105

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 9,983,207.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 10,041,900.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10,041,900.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ALKERMES PLC
(b)	Address of issuer's principal executive offices: CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN, L2, 0000
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: G01767105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 10041900
(b)	Percent of class: 6.1 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 9983207
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 10041900
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	08/14/2025

FAQ

How many Alkermes (ALKS) shares does T. Rowe Price own?

T. Rowe Price Associates, Inc. reports 10,041,900 shares beneficially owned, representing 6.1% of the class, with 9,983,207 shares of sole voting power.

What dates are relevant to this Schedule 13G/A filing for ALKS?

The date of the event requiring filing is June 30, 2025 and the Schedule is signed/dated August 14, 2025.

Under which rule was this Schedule filed and how is the filer classified?

The filing is made under Rule 13d-1(b) and T. Rowe Price Associates, Inc. is identified as an investment adviser (IA).

Does T. Rowe Price claim intent to influence control of Alkermes?

No. The certification states the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control.

Who signed the Schedule 13G/A for T. Rowe Price?

The filing is signed by Ellen York, Vice President for T. Rowe Price Associates, Inc., dated 08/14/2025.